Trial Profile
Efficacy and safety of switching from thrice daily glinide or alpha-GI to twice daily mitiglinide/voglibose combined drug in type 2 diabetes.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Mitiglinide/voglibose (Primary) ; Alpha-glucosidase inhibitors; Meglitinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 Jul 2013 New trial record